Related Experiment Video
Updated: Jun 19, 2026
07:48
Staining Protocols for Human Pancreatic Islets
Published on: May 23, 2012
Human pancreatic islets and diabetes research
John S Kaddis1, Barbara J Olack, Janice Sowinski
1Department of Information Sciences, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010-3000, USA. jkaddis@coh.org
JAMA
|April 16, 2009
Summary
The national Islet Cell Resource Center Consortium provides vital human islets for diabetes research, supporting scientists and advancing therapeutic options. This resource highlights the critical role of human islet research in understanding pancreatic cellular biology and combating diabetes.
Area of Science:
- Endocrinology
- Cell Biology
- Diabetes Research
Background:
- Human islet research is essential for understanding pancreatic cellular biology.
- Developing therapeutic options and prevention strategies for diabetes requires this research.
- The Islet Cell Resource Center Consortium was established to support this critical need.
Purpose of the Study:
- To highlight the importance of the national Islet Cell Resource Center Consortium.
- To demonstrate the value of human islets in diabetes research.
- To discuss the role of islet distribution centers and future directions.
Main Methods:
- The study reviews data on islet distribution, quality, and usage.
- It analyzes the impact of supplied islets on funded grants and publications.
- The study also discusses limitations and future prospects of islet distribution.
Main Results:
- Since 2001, the consortium supplied 297.6 million islet equivalents to 151 scientists.
- Data confirm the significance of human islets for diabetes research.
- Numerous grants and publications resulted from the use of these islets.
Conclusions:
- Human islets are indispensable for advancing diabetes research and developing treatments.
- The Islet Cell Resource Center Consortium plays a crucial role in facilitating this research.
- Understanding limitations and future needs is key for continued progress in islet distribution and diabetes care.
Related Concept Videos
01:26Glucose Absorption Into the Small Intestine
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.